Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

CYP2C9, CYPC19 and CYP2D6 gene profiles and gene susceptibility to drug response and toxicity in Turkish population.

Arici M, Özhan G.

Saudi Pharm J. 2017 Mar;25(3):376-380. doi: 10.1016/j.jsps.2016.09.003. Epub 2016 Sep 17.

2.

Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives.

Zhang YJ, Li MP, Tang J, Chen XP.

Int J Environ Res Public Health. 2017 Mar 14;14(3). pii: E301. doi: 10.3390/ijerph14030301. Review.

3.

Relationship between clopidogrel-related polymorphisms and variable platelet reactivity at 1 year: A cohort study from Han Chinese.

Wang X, Lai Y, Luo Y, Zhang X, Zhou H, Ye Z, Tang J, Liu X.

J Res Med Sci. 2016 Nov 7;21:111. doi: 10.4103/1735-1995.193502. eCollection 2016.

4.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.

Moriyama B, Obeng AO, Barbarino J, Penzak SR, Henning SA, Scott SA, Agúndez J, Wingard JR, McLeod HL, Klein TE, Cross SJ, Caudle KE, Walsh TJ.

Clin Pharmacol Ther. 2016 Dec 16. doi: 10.1002/cpt.583. [Epub ahead of print]

PMID:
27981572
5.
6.

Detection of CYP2C19 Genetic Variants in Malaysian Orang Asli from Massively Parallel Sequencing Data.

Ang GY, Yu CY, Subramaniam V, Abdul Khalid MI, Tuan Abdu Aziz TA, Johari James R, Ahmad A, Abdul Rahman T, Mohd Nor F, Ismail AI, Md Isa K, Salleh H, Teh LK, Salleh MZ.

PLoS One. 2016 Oct 31;11(10):e0164169. doi: 10.1371/journal.pone.0164169. eCollection 2016.

7.

Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine.

Ahmed S, Zhou Z, Zhou J, Chen SQ.

Genomics Proteomics Bioinformatics. 2016 Oct;14(5):298-313. doi: 10.1016/j.gpb.2016.03.008. Epub 2016 Oct 8. Review.

8.

Platelet Function Testing-Guided Antiplatelet Therapy.

Lenk E, Spannagl M.

EJIFCC. 2013 Feb 21;24(3):90-6. eCollection 2013 Feb.

9.

Progressing Preemptive Genotyping of CYP2C19 Allelic Variants for Sickle Cell Disease Patients.

Jaja C, Barrett N, Patel N, Lyon M, Xu H, Kutlar A.

Genet Test Mol Biomarkers. 2016 Oct;20(10):609-615. Epub 2016 Aug 23.

PMID:
27551817
10.

"Influence of methadone on clopidogrel in addicts on methadone maintenance therapy" Drug interaction between methadone and clopidogrel.

Fallah F, Hamidikenari A, Sajadi SN, Sajadi SR, Shiran M.

Caspian J Intern Med. 2016 Spring;7(2):133-5.

11.

Association of PON1, P2Y12 and COX1 with Recurrent Ischemic Events in Patients with Extracranial or Intracranial Stenting.

Li XQ, Ma N, Li XG, Wang B, Sun SS, Gao F, Mo DP, Song LG, Sun X, Liu L, Zhao XQ, Wang YL, Wang YJ, Zhao ZG, Miao ZR.

PLoS One. 2016 Feb 12;11(2):e0148891. doi: 10.1371/journal.pone.0148891. eCollection 2016.

12.

Genotype and allele frequency of CYP2C19*17 in a healthy Iranian population.

Payan M, Tajik N, Rouini MR, Ghahremani MH.

Med J Islam Repub Iran. 2015 Oct 3;29:269. eCollection 2015.

13.

Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls.

Winter MP, Koziński M, Kubica J, Aradi D, Siller-Matula JM.

Postepy Kardiol Interwencyjnej. 2015;11(4):259-80. doi: 10.5114/pwki.2015.55596. Epub 2015 Jan 12. Review.

14.

Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content.

Shirasaka Y, Chaudhry AS, McDonald M, Prasad B, Wong T, Calamia JC, Fohner A, Thornton TA, Isoherranen N, Unadkat JD, Rettie AE, Schuetz EG, Thummel KE.

Pharmacogenomics J. 2016 Aug;16(4):375-87. doi: 10.1038/tpj.2015.58. Epub 2015 Sep 1.

15.

Implementation of Cell Samples as Controls in National Proficiency Testing for Clopidogrel Therapy-Related CYP2C19 Genotyping in China: A Novel Approach.

Lin G, Yi L, Zhang K, Wang L, Zhang R, Xie J, Li J.

PLoS One. 2015 Jul 28;10(7):e0134174. doi: 10.1371/journal.pone.0134174. eCollection 2015.

16.

A study on the impact of CYP2C19 genotype and platelet reactivity assay on patients undergoing PCI.

Rath PC, Chidambaram S, Rath P, Dikshit B, Naik S, Sahoo PK, Das B, Mahalingam M, Khandrika L, Jain J.

Indian Heart J. 2015 Mar-Apr;67(2):114-21. doi: 10.1016/j.ihj.2015.03.017. Epub 2015 Apr 27.

17.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.

Hicks JK, Bishop JR, Sangkuhl K, Müller DJ, Ji Y, Leckband SG, Leeder JS, Graham RL, Chiulli DL, LLerena A, Skaar TC, Scott SA, Stingl JC, Klein TE, Caudle KE, Gaedigk A; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2015 Aug;98(2):127-34. doi: 10.1002/cpt.147. Epub 2015 Jun 29. Review.

18.

Hydroxylation index of omeprazole in relation to CYP2C19 polymorphism and sex in a healthy Iranian population.

Payan M, Rouini MR, Tajik N, Ghahremani MH, Tahvilian R.

Daru. 2014 Dec 11;22:81. doi: 10.1186/s40199-014-0081-6.

19.

Bleeding risk stratification in an era of aggressive management of acute coronary syndromes.

Abu-Assi E, Raposeiras-Roubín S, García-Acuña JM, González-Juanatey JR.

World J Cardiol. 2014 Nov 26;6(11):1140-8. doi: 10.4330/wjc.v6.i11.1140. Review.

20.

Antiplatelet therapy for carotid artery stenting.

Enomoto Y, Yoshimura S.

Interv Neurol. 2013 Sep;1(3-4):151-63. doi: 10.1159/000351686. Review.

Supplemental Content

Support Center